Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis.
Conformational Landscape of N-Glycosylated Peptides Detecting Autoantibodies in Multiple Sclerosis, Revealed by Hamiltonian Replica Exchange.
Patients with migraine do not have MRI-visible cortical lesions.
Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies.
Neural differentiation of patient specific iPS cells as a novel approach to study the pathophysiology of multiple sclerosis.
Amiloride Clinical Trial In Optic Neuritis (ACTION)
Gilenya prescribing information
Pharmaceutical approval update.
Apitope Announces Completion of Enrolment in Phase IIA Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient.
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.
UW-SES: A new self-efficacy scale for people with disabilities.
First NW patient to receive OHSU/VAMC-invented MS drug
Mycoplasma pneumonia seroposivity in Iranian patients with relapsing-remitting multipl sclerosis: a randomized case-control study.
Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.
Video game training enhances cognitive control in older adults.
Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
Distinct profiles of myelin distribution along single axons of pyramidal neurons in the neocortex.
Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation.
Pregnancy level of estrogen attenuates experimental autoimmune encephalomyelitis in both ovariectomized and pregnant C57BL/6 mice through expansion of Treg and Th2 cells.
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Metabolomics of cerebrospinal fluid reveals changes in the central nervous system metabolism in a rat model of multiple sclerosis.
Pages
« first
‹ previous
…
142
143
144
145
146
147
148
149
150
…
next ›
last »